Biopharma's Evolution and Future Resilience in Asia
BioSpectrum Asia|BioSpectrum Asia Dec 2023
As the world emerges from the COVID-19 crisis, the global biopharma industry remains under spotlight. Recent advancements in the sector such as MRNA-based vaccines, use of artificial intelligence Al) in drug discovery, exploration of cell and gene therapies, have the potential to reshape lives, offering hope in the face of looming threats such as pandemics and antimicrobial resistance. Based on five pillars supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, and government policy and regulation, Cytiva has unveiled the findings of the 2023 Global Biopharma Resilience Index, to help us identify the gaps in the industry now, and how to mitigate current challenges for a stronger future within Asia Pacific and Southeast Asia.
Ayesha Siddiqui
Biopharma's Evolution and Future Resilience in Asia

The rapid deployment of mRNA vaccines in response to COVID-19 catalysed a new era in vaccinology and reignited interest in nucleic acid therapies. Artificial intelligence (AI)-enabled research is accelerating therapeutic development, with the opportunity to radically improve patient outcomes. Breakthroughs in cell and gene therapies (CGTs) have the potential to treat genetic diseases. Despite these breakthroughs and opportunities, however, sustained high growth is not a certainty for the industry.

The emergency funding boost of 2020 and 2021 has fallen away, with financing for small and mid-size biotech firms in novel therapeutics pulling back in 2021. The funding landscape remains challenging in 2023 as cost of capital, economic insecurity, talent shortages, regulatory challenges, and disruption all continue to affect the sector.

To assess the strength of the global industry in these turbulent times, Cytiva created the Global Biopharma Resilience Index. Introduced in 2021, the index scores and ranks countries on five factors: Supply chain resilience; Talent pool; R&D ecosystem; Manufacturing agility; Government policy and regulation. According to the 2023 index, based on data from a survey of 1250 pharma and biopharma executives across 22 countries, performance across three of the five pillars i.e. talent pool, R&D ecosystem, and government policy and regulation, has weakened. The pillar that has suffered most over the past two years is the R&D ecosystem, which fell from 6.54 in 2021 to 5.22 in 2023.

Denne historien er fra BioSpectrum Asia Dec 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra BioSpectrum Asia Dec 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIOSPECTRUM ASIASe alt
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024